RS63776B1 - Modulatori somatostatina i njihove upotrebe - Google Patents
Modulatori somatostatina i njihove upotrebeInfo
- Publication number
- RS63776B1 RS63776B1 RS20221103A RSP20221103A RS63776B1 RS 63776 B1 RS63776 B1 RS 63776B1 RS 20221103 A RS20221103 A RS 20221103A RS P20221103 A RSP20221103 A RS P20221103A RS 63776 B1 RS63776 B1 RS 63776B1
- Authority
- RS
- Serbia
- Prior art keywords
- somatostatin modulators
- somatostatin
- modulators
- Prior art date
Links
- 102000005157 Somatostatin Human genes 0.000 title 1
- 108010056088 Somatostatin Proteins 0.000 title 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title 1
- 229960000553 somatostatin Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662362493P | 2016-07-14 | 2016-07-14 | |
| US201662411338P | 2016-10-21 | 2016-10-21 | |
| EP17828375.0A EP3484865B1 (en) | 2016-07-14 | 2017-07-12 | Somatostatin modulators and uses thereof |
| PCT/US2017/041694 WO2018013676A1 (en) | 2016-07-14 | 2017-07-12 | Somatostatin modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS63776B1 true RS63776B1 (sr) | 2022-12-30 |
Family
ID=60941935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20221103A RS63776B1 (sr) | 2016-07-14 | 2017-07-12 | Modulatori somatostatina i njihove upotrebe |
Country Status (24)
| Country | Link |
|---|---|
| US (6) | US9896432B2 (sr) |
| EP (2) | EP4163276A1 (sr) |
| JP (2) | JP6967577B2 (sr) |
| KR (2) | KR20210134838A (sr) |
| CN (2) | CN109715612B (sr) |
| AU (2) | AU2017296392B2 (sr) |
| BR (1) | BR112019000692A8 (sr) |
| CA (1) | CA3030423A1 (sr) |
| DK (1) | DK3484865T3 (sr) |
| ES (1) | ES2931472T3 (sr) |
| HR (1) | HRP20221279T1 (sr) |
| HU (1) | HUE060182T2 (sr) |
| IL (1) | IL264178B2 (sr) |
| LT (1) | LT3484865T (sr) |
| MX (1) | MX2019000588A (sr) |
| NZ (1) | NZ750174A (sr) |
| PL (1) | PL3484865T3 (sr) |
| PT (1) | PT3484865T (sr) |
| RS (1) | RS63776B1 (sr) |
| SG (1) | SG11201900349VA (sr) |
| TW (1) | TWI789355B (sr) |
| UA (1) | UA125393C2 (sr) |
| WO (1) | WO2018013676A1 (sr) |
| ZA (1) | ZA201900317B (sr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201900349VA (en) | 2016-07-14 | 2019-02-27 | Crinetics Pharmaceuticals Inc | Somatostatin modulators and uses thereof |
| CN110650951B (zh) | 2017-03-16 | 2023-02-24 | 克林提克斯医药股份有限公司 | 促生长素抑制素调节剂及其用途 |
| US11028068B2 (en) | 2017-07-25 | 2021-06-08 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| SI3740475T1 (sl) * | 2018-01-17 | 2022-09-30 | Crinetics Pharmaceuticals, Inc. | Postopek izdelave somatostatin modulatorjev |
| WO2019157458A1 (en) * | 2018-02-12 | 2019-08-15 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| US20210246128A1 (en) * | 2018-05-29 | 2021-08-12 | Council Of Scientific & Industrial Research | Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof |
| EP3853218A4 (en) | 2018-09-18 | 2022-02-16 | Crinetics Pharmaceuticals, Inc. | SOMATOSTATIN MODULATORS AND USES THEREOF |
| US20220267295A1 (en) * | 2019-07-17 | 2022-08-25 | Crinetics Pharmaceuticals, Inc. | Crystalline forms of somatostatin modulators |
| EP4013748A4 (en) | 2019-08-14 | 2023-08-09 | Crinetics Pharmaceuticals, Inc. | NON-PEPTIDIC SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND THEIR USE |
| US11266641B1 (en) | 2020-09-09 | 2022-03-08 | Crinetics Pharmaceuticals, Inc. | Formulations of a somatostatin modulator |
| US11773076B2 (en) | 2021-02-17 | 2023-10-03 | Crinetics Pharmaceuticals, Inc. | Crystalline forms of a somatostatin modulator |
| MX2023013942A (es) * | 2021-05-25 | 2023-12-08 | Crinetics Pharmaceuticals Inc | Usos de un modulador de somatostatina para el tratamiento de enfermedades. |
| KR20240068733A (ko) | 2021-09-28 | 2024-05-17 | 덴카 주식회사 | 클로로프렌계 블록 공중합체, 라텍스, 라텍스 조성물, 및 고무 조성물 |
| WO2023137018A1 (en) * | 2022-01-11 | 2023-07-20 | Crinetics Pharmaceuticals, Inc. | Uses of a somatostatin modulator for the treatment of carcinoid syndrome |
| WO2023238112A1 (en) | 2022-06-10 | 2023-12-14 | Assia Chemical Industries Ltd. | Solid state forms of paltusotine and process for preparation thereof |
| WO2024089668A1 (en) * | 2022-10-28 | 2024-05-02 | Basecamp Bio Inc. | Somatostatin receptor 2 agonists and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1035154A (en) | 1910-05-16 | 1912-08-13 | Ernest G Clark | Machine for rectifying perforated music and masters. |
| FR2802206B1 (fr) | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
| US20050009815A1 (en) | 2001-11-27 | 2005-01-13 | Devita Robert J. | 4-Aminoquinoline compounds |
| DE60320529T2 (de) * | 2002-02-04 | 2009-06-10 | F. Hoffmann-La Roche Ag | Chinolinderivate als npy antagonisten |
| WO2005024416A1 (en) | 2003-09-05 | 2005-03-17 | Binghe Wang | Water soluble boronic acid fluorescent reporter compounds and methods of use thereof |
| JP2008506695A (ja) * | 2004-07-13 | 2008-03-06 | グラクソ グループ リミテッド | 抗細菌剤 |
| US20060183763A1 (en) | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
| ZA200805511B (en) | 2005-12-05 | 2010-02-24 | Xenoport Inc | Levodopa prodrug mesylate, compositions thereof, and uses thereof |
| JP2009527562A (ja) | 2006-02-21 | 2009-07-30 | アムゲン インコーポレイティッド | ホスホジエステラーゼ１０阻害剤としてのシンノリン誘導体 |
| AU2007223801A1 (en) | 2006-03-08 | 2007-09-13 | Amgen Inc. | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors |
| JP2009530276A (ja) * | 2006-03-13 | 2009-08-27 | メルク エンド カムパニー インコーポレーテッド | ソマトスタチンアゴニスト |
| EA201100426A1 (ru) | 2008-09-02 | 2011-10-31 | Новартис Аг | Бициклические ингибиторы киназы |
| GB0818241D0 (en) * | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
| MX342879B (es) | 2010-07-30 | 2016-10-14 | Oncotherapy Science Inc * | Derivados de quinolina e inhibidores de cinasa de cremallera de leucina embrionica materna que los contienen. |
| AU2012258977A1 (en) | 2011-05-23 | 2014-01-16 | Imago Pharmaceuticals, Inc. | Inhibitors of LRRK2 kinase activity |
| US8871756B2 (en) | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
| DE102011113749A1 (de) | 2011-09-14 | 2013-03-14 | Aicuris Gmbh & Co. Kg | Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole |
| US20140228417A1 (en) | 2011-10-05 | 2014-08-14 | Mapi Pharma Ltd. | Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids |
| EP2871179A4 (en) * | 2012-07-03 | 2016-03-16 | Ono Pharmaceutical Co | CONNECTION WITH AGONISTIC EFFECT ON THE SOMATOSTATIN RECEPTOR AND ITS USE FOR MEDICAL PURPOSES |
| ES2628365T3 (es) * | 2012-10-16 | 2017-08-02 | Janssen Pharmaceutica N.V. | Moduladores de quinolinilo unidos a fenilo de ROR-GAMA-T |
| TWI628175B (zh) | 2013-09-30 | 2018-07-01 | 日商小野藥品工業股份有限公司 | 具有體抑素受體致效活性的化合物及其醫藥用途 |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| CA2943643A1 (en) | 2014-03-24 | 2015-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| WO2017003723A1 (en) | 2015-07-01 | 2017-01-05 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| EP3317278B1 (en) | 2015-07-01 | 2021-04-14 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| EP3889145B1 (en) | 2015-12-17 | 2024-02-21 | Merck Patent GmbH | 8-cyano-5-piperidino-quinolines as tlr7/8 antagonists and their uses for treating immune disorders |
| WO2018009735A1 (en) | 2016-07-07 | 2018-01-11 | Plantex Ltd. | Solid state forms of palbociclib dimesylate |
| SG11201900349VA (en) | 2016-07-14 | 2019-02-27 | Crinetics Pharmaceuticals Inc | Somatostatin modulators and uses thereof |
| SI3740475T1 (sl) | 2018-01-17 | 2022-09-30 | Crinetics Pharmaceuticals, Inc. | Postopek izdelave somatostatin modulatorjev |
| EP3853218A4 (en) | 2018-09-18 | 2022-02-16 | Crinetics Pharmaceuticals, Inc. | SOMATOSTATIN MODULATORS AND USES THEREOF |
| US20220267295A1 (en) | 2019-07-17 | 2022-08-25 | Crinetics Pharmaceuticals, Inc. | Crystalline forms of somatostatin modulators |
| US11266641B1 (en) | 2020-09-09 | 2022-03-08 | Crinetics Pharmaceuticals, Inc. | Formulations of a somatostatin modulator |
-
2017
- 2017-07-12 SG SG11201900349VA patent/SG11201900349VA/en unknown
- 2017-07-12 UA UAA201901274A patent/UA125393C2/uk unknown
- 2017-07-12 ES ES17828375T patent/ES2931472T3/es active Active
- 2017-07-12 US US15/647,758 patent/US9896432B2/en active Active
- 2017-07-12 EP EP22194733.6A patent/EP4163276A1/en not_active Withdrawn
- 2017-07-12 HU HUE17828375A patent/HUE060182T2/hu unknown
- 2017-07-12 LT LTEPPCT/US2017/041694T patent/LT3484865T/lt unknown
- 2017-07-12 KR KR1020217035692A patent/KR20210134838A/ko not_active Application Discontinuation
- 2017-07-12 RS RS20221103A patent/RS63776B1/sr unknown
- 2017-07-12 IL IL264178A patent/IL264178B2/en unknown
- 2017-07-12 KR KR1020197004427A patent/KR102324042B1/ko active IP Right Grant
- 2017-07-12 NZ NZ750174A patent/NZ750174A/en unknown
- 2017-07-12 CA CA3030423A patent/CA3030423A1/en active Pending
- 2017-07-12 WO PCT/US2017/041694 patent/WO2018013676A1/en unknown
- 2017-07-12 EP EP17828375.0A patent/EP3484865B1/en active Active
- 2017-07-12 CN CN201780056677.9A patent/CN109715612B/zh active Active
- 2017-07-12 MX MX2019000588A patent/MX2019000588A/es unknown
- 2017-07-12 JP JP2019500810A patent/JP6967577B2/ja active Active
- 2017-07-12 DK DK17828375.0T patent/DK3484865T3/da active
- 2017-07-12 PL PL17828375.0T patent/PL3484865T3/pl unknown
- 2017-07-12 AU AU2017296392A patent/AU2017296392B2/en active Active
- 2017-07-12 HR HRP20221279TT patent/HRP20221279T1/hr unknown
- 2017-07-12 BR BR112019000692A patent/BR112019000692A8/pt active Search and Examination
- 2017-07-12 CN CN202211105259.3A patent/CN115557929A/zh active Pending
- 2017-07-12 PT PT178283750T patent/PT3484865T/pt unknown
- 2017-07-14 TW TW106123557A patent/TWI789355B/zh active
- 2017-12-20 US US15/849,409 patent/US10351547B2/en active Active
-
2019
- 2019-01-16 ZA ZA2019/00317A patent/ZA201900317B/en unknown
- 2019-05-08 US US16/407,031 patent/US10597377B2/en active Active
- 2019-12-12 US US16/712,620 patent/US10875839B2/en active Active
-
2020
- 2020-10-26 US US17/080,358 patent/US11414397B2/en active Active
- 2020-11-24 AU AU2020277122A patent/AU2020277122A1/en not_active Abandoned
-
2021
- 2021-10-22 JP JP2021173304A patent/JP2022028675A/ja not_active Ceased
-
2022
- 2022-07-01 US US17/810,497 patent/US20220380337A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201900317B (en) | Somatostatin modulators and uses thereof | |
| HK1255034A1 (zh) | 生長抑素調節劑及其用途 | |
| IL266570B (en) | Syntac polypeptides and their uses | |
| IL269241A (en) | Somatostatin modulators and their uses | |
| IL273236A (en) | Pyrazolopyrimidine compounds and their uses | |
| IL247847B (en) | ror gamma modulator and their use | |
| HK1255074A1 (zh) | 生長抑素調節劑及其用途 | |
| EP3658560A4 (en) | SOMATOSTAT IN MODULATORS AND USES THEREOF | |
| HK1247122A1 (zh) | 組合及其用途 | |
| IL254241A0 (en) | Etv2 and its uses | |
| GB201410031D0 (en) | Polypeptides and uses thereof | |
| IL264473A (en) | GPR156 variants and their uses | |
| IL273671A (en) | Cornoline variants and their use | |
| ZA201905513B (en) | Rorgamma modulators and uses thereof | |
| ZA201905511B (en) | Rorgamma modulators and uses thereof | |
| GB201614224D0 (en) | Compounds and uses thereof | |
| ZA201606656B (en) | Ror-gamma modulators and uses thereof | |
| GB201613143D0 (en) | Polypeptides and uses thereof | |
| GB201613142D0 (en) | Polypeptides and uses thereof |